OKYO Pharma Limited
OKYO · NASDAQ
3/31/2025 | 10/1/2024 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $2 | – | $1 | $1 |
| Short-Term Investments | $0 | – | $0 | $0 |
| Receivables | $2 | – | $2 | $1 |
| Inventory | $0 | – | $0 | $0 |
| Other Curr. Assets | $0 | – | $0 | $0 |
| Total Curr. Assets | $4 | – | $3 | $2 |
| Property Plant & Equip (Net) | $0 | – | $0 | $0 |
| Goodwill | $0 | – | $0 | $0 |
| Intangibles | $0 | – | $0 | $0 |
| Long-Term Investments | $0 | – | $0 | $0 |
| Tax Assets | $0 | – | $0 | $0 |
| Other NC Assets | $0 | – | $0 | $0 |
| Total NC Assets | $0 | – | $0 | $0 |
| Other Assets | $0 | – | $0 | $0 |
| Total Assets | $4 | – | $3 | $2 |
| Liabilities | – | – | – | – |
| Payables | $8 | – | $10 | $6 |
| Short-Term Debt | $0 | – | $0 | $0 |
| Tax Payable | $0 | – | $0 | $0 |
| Deferred Revenue | $0 | – | $0 | $0 |
| Other Curr. Liab. | $1 | – | $0 | $1 |
| Total Curr. Liab. | $9 | – | $10 | $7 |
| LT Debt | $0 | – | $0 | $0 |
| Deferred Rev, NC | $0 | – | $0 | $0 |
| Deferred Tax Liab, NC | $0 | – | $0 | $0 |
| Other NC Liab. | $0 | – | $0 | $0 |
| Total NC Liab. | $0 | – | $0 | $0 |
| Other Liabilities | $0 | – | $0 | $0 |
| Cap. Leases | $0 | – | $0 | $0 |
| Total Liabilities | $9 | – | $10 | $7 |
| Equity | – | – | – | – |
| Pref Stock | $0 | – | $0 | $0 |
| Common Stock | $147 | – | $144 | $143 |
| Retained Earnings | -$143 | – | -$145 | -$143 |
| AOCI | -$11 | – | -$6 | -$11 |
| Other Equity | $147 | – | $144 | $5 |
| Total Equity | -$6 | – | -$7 | -$6 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | – | $0 | $0 |
| Total Liab. & Tot. Equity | $4 | – | $3 | $2 |
| Net Debt | -$2 | $0 | -$1 | -$1 |